. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Ann Surg Oncol. 2013 Jun 26;20(12):3899–3904. doi: 10.1245/s10434-013-3087-2

TABLE 4.

Impact of obesity on survival of patients with peritoneal surface disease treated with CRS/HIPEC

Obesity level	Low-grade appendiceal				High-grade appendiceal				Colon

	n	Median OS (months)	5/10-y survival (%)	p^a	n	Median OS (months)	3-y survival (%)	p^a	n	Median OS (months)	3/5-y survival (%)	p^a
Non-obese	162	107	70/47	Ref	67	19	28	Ref	101	18	27/15	Ref
All obese	61	76	59/37	0.32	15	17	20	0.40	55	18	22/9	0.42
Moderately obese (BMI 30–34.9 kg/m²)	35	108	68/45	0.88	9	13	22	0.38	37	19	20/9	0.71
Severely obese (BMI ≥ 35 kg/m²)	26	54	48/29	0.05	6	17	–	–	18	15	24/8	0.25

CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy, OS overall survival, BMI body mass index

Compared to non-obese cohort